Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-FU with or without cetuximab in elderly/frail KRAS wild type metastatic colorectal cancer based on geriatric assessment
2011-002947-83Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Nov 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in metastatic colorectal adenocarcinoma (mCRC) comparing 5-fluorouracil monotherapy with 5-fluorouracil plus cetuximab (2 arms). Primary endpoint: Progression-free survival. Started Nov 2012; status: completed.
02
Drugs
cetuximabfluorouracil
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2011-002947-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002947-83.